2018
Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer
Kuang Y, Siddiqui B, Hu J, Pun M, Cornwell M, Buchwalter G, Hughes ME, Wagle N, Kirschmeier P, Jänne PA, Paweletz CP, Lin NU, Krop IE, Barry WT, Winer EP, Brown M, Jeselsohn R. Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. Npj Breast Cancer 2018, 4: 22. PMID: 30083595, PMCID: PMC6072793, DOI: 10.1038/s41523-018-0075-5.Peer-Reviewed Original ResearchMetastatic breast cancerESR1 mutationsBreast cancerMetastatic settingClinicopathological featuresPIK3CA mutationsAromatase inhibitorsER-positive metastatic breast cancerDetailed clinical dataSpecific systemic treatmentMetastatic treatmentDistant recurrenceMetastatic diseaseSystemic treatmentPrimary diseaseEndocrine resistanceCDK4/6 inhibitorsPathological featuresFulvestrant treatmentClinical dataPrior treatmentSignificant associationPatientsCancerPrevalence
2001
Knowledge, Satisfaction, and Perceived Cancer Risk among Women Diagnosed with Ductal Carcinoma In Situ
Bluman L, Borstelmann N, Rimer B, Iglehart J, Winer E. Knowledge, Satisfaction, and Perceived Cancer Risk among Women Diagnosed with Ductal Carcinoma In Situ. Journal Of Women's Health 2001, 10: 589-598. PMID: 11559456, DOI: 10.1089/15246090152543175.Peer-Reviewed Original ResearchConceptsDuctal carcinomaBreast cancerInvasive breast cancerSelf-administered questionnaireDCIS diagnosisTumor RegistryDCISCancer riskFuture healthKnowledge deficitsPsychological distressWomenCarcinomaCancerRisk perceptionCareFuture studiesFuture investigationsAreas of concernPrognosisRecurrenceWidespread useMetastasisRegistryPrevalence